Key Takeaways from the Pharmaceutical, Biotech, & Medical Device Round Table – March 2023

    Apr 03, 2023 @ 06:29 PM / by Jade Chang

    Summer Weather Anne Benjamin

    Photo by AIRINCer Anne Benjamin

    Key Takeaways from the Pharmaceutical, Biotech, and Medical Device Round Table – March 2023

    AIRINC facilitated another Pharma, Biotech, and medical device round table session with strategic leaders from around the globe to share industry insights and discuss their program challenges and focuses for 2023.

    Remote Work

    Companies are still struggling how to manage remote work arrangements. Companies need to be cognizant of a growing list of concerns: corporate tax implications, the precedence among the global population, and being mindful of mandated hybrid arrangements. For companies who allow global remote work arrangements, they noted relocation benefits are not provided, and the employee must move to local contract and terms.

    With the growing desire to be ‘remote’ and work from anywhere, companies are still trying to find the right technology to track where people are and retention rates. Have you found the right technology for this population?

    Short-Term to Long-term Assignments

    When ST assignments span into LTA territory, are companies changing benefits after the 12-month mark? Some companies are struggling to move employees to a COLA from a per diem when assignment lengths surpass 12 months. Issues are arising because employees have become accustomed to a full expenditure at host. When converting ST to LT assignment, companies noted upfront conversations with the employee and better talent planning at the beginning are the best solutions to minimize employee concerns and set their expectations for the converted assignment.

    Inflation

    Globally, we are all seeing high inflation rates for goods and services, housing, everything! Companies discussed how they’re addressing high inflation from both a COLA and lump sum perspective. Many companies are continuing to update their COLA on a regular cadence, based on our LTA survey 73% of pharmas are updating COLA on a semi-annual basis, to capture inflation changes more regularly. For lump sums, we’re seeing more effort to review these budgets on an annual basis to ensure they’re aligning to current market.

     

    Are you addressing these areas differently than your peers? Interested in joining our next industry event? Please contact us today.

    Let's Talk

     

     

    More recent blog posts:

    Topics: Mobility Policy, AIRINC News, Thought Leadership, networking, Roundtable

    Jade Chang

    Written by Jade Chang

    Jade joined AIRINC’s Client Engagement group in 2015. Since that time, she has specialized in servicing clients throughout the Northeast U.S. Jade primarily services large managed programs focused within the Pharmaceutical and Banking industries. Also a member of AIRINC’s Advisory Services team, she has worked on a variety of projects across a multitude of industries. Jade’s Advisory Services focus is on benchmarking. Jade received her B.A. in Economics from Boston University and is based in New York, NY.